iFR, or instantaneous wave-free ratio, is a pressure-based test used during cardiac catheterization to measure how much a narrowed coronary artery is restricting blood flow to the heart. It produces a number between 0 and 1, with a value of 0.89 or below indicating that the blockage is significant enough to cause ischemia and likely warrants treatment with a stent or bypass surgery. The test works without requiring any drugs to stress the heart, making it faster and more comfortable than the older standard, fractional flow reserve (FFR).
How iFR Works
During a coronary angiogram, a cardiologist can see a narrowing in an artery on imaging, but the image alone doesn’t reveal whether that narrowing is actually starving the heart muscle of blood. iFR answers that functional question. A thin pressure-sensing wire is threaded through the artery and positioned just past the narrowed segment. The wire simultaneously records blood pressure on both sides of the blockage.
What makes iFR unique is the specific moment it takes its reading. During each heartbeat, there’s a brief window in diastole (the resting phase between beats) called the “wave-free period.” In this window, the tiny blood vessels downstream are relaxed and stable, and competing pressure waves that would muddy the measurement have largely died down. iFR captures the pressure ratio during this clean window: the pressure after the blockage divided by the pressure before it. A healthy artery would show nearly equal pressures on both sides, producing a ratio close to 1.0. The more a blockage restricts flow, the lower the ratio drops.
iFR vs. FFR
For decades, FFR was the gold standard for judging whether a coronary blockage needed treatment. FFR works on the same basic principle (comparing pressures across a lesion), but it requires injecting a drug called adenosine to dilate the blood vessels and push blood flow to its maximum. Only under that stressed, “hyperemic” condition can FFR get its reading. The FFR threshold for significant ischemia is 0.80 or below.
iFR skips the adenosine entirely. Instead of artificially stressing the circulation, it exploits that naturally occurring wave-free period when conditions are already favorable for an accurate measurement. This difference has several practical consequences:
- No drug side effects. Adenosine commonly causes breathlessness, chest tightness, and flushing. iFR avoids all of that.
- Faster procedure. Without the time needed to set up and administer an adenosine infusion and wait for peak effect, iFR readings are essentially instantaneous.
- Lower cost. A cost analysis found iFR-guided procedures saved roughly $681 per patient in Nordic health systems and about $1,024 per patient in the United States compared to FFR-guided procedures, primarily by eliminating the drug and reducing procedure time.
What the Evidence Shows
Two large randomized trials, DEFINE-FLAIR and iFR-SWEDEHEART, compared iFR-guided and FFR-guided treatment decisions head to head. Both trials tracked a composite of death, heart attack, and emergency repeat procedures at one year, and both met their non-inferiority criteria, meaning iFR performed as well as FFR for guiding stent decisions over that time frame. Notably, the iFR-guided approach led to fewer stent placements overall.
These results earned iFR a Class 1A guideline recommendation in 2019, the strongest level of endorsement, matching the Class 1A recommendation FFR had received in 2014. Both European and American guidelines now recognize iFR as an equivalent option for assessing intermediate coronary blockages.
Longer-term data have added some nuance. A pooled analysis of both trials at five years found that iFR-guided management was associated with a higher rate of death compared to FFR-guided management, with a risk ratio of 1.34. This finding has prompted ongoing discussion among cardiologists about whether the two tests are truly interchangeable over the long run, or whether certain patient groups might benefit more from one approach over the other.
When iFR Is Especially Useful
iFR is most commonly used for “intermediate” blockages, those that look moderate on an angiogram (typically 40% to 70% narrowing) and leave the cardiologist uncertain about whether a stent would help. In these gray-zone cases, visual assessment alone is unreliable, and a pressure measurement provides the objective data needed to make the call.
One advantage iFR holds over FFR is in evaluating tandem lesions, where two or more narrowings sit in the same artery. Because iFR doesn’t require a drug-induced hyperemic state, it can assess the contribution of each individual narrowing separately, helping the cardiologist decide which segments actually need stenting and which can be left alone. Early trial data in patients with tandem or long, diffuse disease showed this approach reduced total stent length compared to decisions based on angiography alone, though the clinical benefit of shorter stenting is still being evaluated in larger studies.
iFR can also be used in non-culprit vessels during acute coronary syndromes. If a patient comes in with a heart attack caused by one artery but has additional blockages in other arteries, iFR can help assess those secondary lesions without subjecting an already-stressed patient to adenosine.
What the Procedure Feels Like
If you’re having an iFR measurement, you’ll already be in the catheterization lab for a coronary angiogram, with a catheter inserted through your wrist or groin. The iFR wire is advanced through the same catheter, so there’s no additional puncture or incision. Most patients don’t feel the wire itself. The reading takes seconds, and because no adenosine is involved, you won’t experience the flushing, chest pressure, or shortness of breath that FFR patients commonly report. If the iFR value comes back at 0.89 or below, the cardiologist will typically proceed with stenting during the same session. If it’s above 0.89, the blockage is generally managed with medications alone.